Extended Data Fig. 3: Percentage of stopped trials predicted to be halted due to Safety or side effects or the COVID-19 pandemic as a fraction of all the trials by predominant therapeutic area.
From: Genetic factors associated with reasons for clinical trial stoppage
Indications with multiple possible therapeutic areas were associated with the most severe area (for example Oncology). Overall incidence when considering all therapeutic areas was 5% for COVID-19 and 3.3% for Safety or side effects.
